BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10970951)

  • 1. [Prolactinoma in man: clinical and histological characteristics].
    Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
    Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.
    Delgrange E; Trouillas J; Maiter D; Donckier J; Tourniaire J
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2102-7. PubMed ID: 9215279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-related differences in prolactin secretion in pituitary prolactinomas.
    Nishioka H; Haraoka J; Akada K; Azuma S
    Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Invasive giant prolactinoma].
    Domínguez Ugidos LJ; Martínez Subías J; Urpegui García A; Sancho Serrano E; Alfonso Collado JI; Vallés Varela H
    Acta Otorrinolaringol Esp; 1998 Mar; 49(2):156-8. PubMed ID: 9650316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in macroprolactinomas: study of clinical features, outcome of patients and ki-67 expression in tumor tissue.
    Fainstein Day P; Glerean M; Lovazzano S; Pietrani M; Christiansen S; Balzaretti M; Kozak A; Carrizo A
    Front Horm Res; 2010; 38():50-58. PubMed ID: 20616495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth potential of prolactinomas in men: is it really different from women?
    Nishioka H; Haraoka J; Akada K
    Surg Neurol; 2003 May; 59(5):386-90; discussion 390-1. PubMed ID: 12765811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A; Bhansali A; Masoodi SR
    Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of prolactin-secreting pituitary tumors with bromocriptine].
    Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y
    Harefuah; 1990 Feb; 118(3):141-5. PubMed ID: 2341064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.
    Hajder M; Hajder E; Dervisefendic M; Samardzic R; Alic E
    Med Arch; 2013; 67(3):181-4. PubMed ID: 23848038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas.
    Essaïs O; Bouguerra R; Hamzaoui J; Marrakchi Z; Hadjri S; Chamakhi S; Zidi B; Ben Slama C
    Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):524-31. PubMed ID: 12527854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prolactinoma in a child showing high MIB-1 labeling index: a case report].
    Akamine S; Miyamoto T; Sugiura Y; Takehara S; Hiramatsu H; Nishizawa S; Yokota N
    No Shinkei Geka; 2000 Jun; 28(6):547-53. PubMed ID: 10875113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
    Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
    Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
    Ma W; Ikeda H; Yoshimoto T
    Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-related differences in prolactinomas. A clinicopathological study.
    Schaller B
    Neuro Endocrinol Lett; 2005 Apr; 26(2):152-9. PubMed ID: 15855888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.